B asal cell carcinoma (BCC) of the skin constitutes approximately 75% of all malignant skin tumors [1] and it is now the most common malignancy in the Caucasian population. [1, 2] The incidence rate varies significantly around the world, ranging from 2 in East Asia to 1600/100.000 per year in Queensland, Australia. [2] This oncological entity represents a heterogeneous group of tumors with a variable clinical manifestation, histomorphology, and biological behavior. Although it is usually a slow-growing neoplasia with only minimal metastatic potential, some subtypes grow aggressively, causing extensive tissue destruction. [1] The disease can be classified into sporadic (non-syndromic) and syndromic (hereditary) forms. In the first group, which comprises the vast majority of the cases, the affected individuals do not have any genodermatosis susceptible to developing cutaneous malignancies. BCC lesions usually occur in middle-aged and older adults. In the second group, the patients suffer from a genetic skin disorder (e.g., Gorlin-Goltz syndrome, Bazex syndrome, xeroderma pigmentosum), which predisposes them to BCC development at an early age. One of the interesting clinical features of this cancer is a marked variation in tumor number, sites, and accrual (number of tumors per year from the first presentation) between individuals. [3-5] Some patients have developed only 1 BCC lesion throughout their life with no impact on their health status. On the other hand, a significant pro-An interesting clinical feature of basal cell carcinoma (BCC) of the skin is a marked variation in tumor number, sites, and accrual. Some individuals develop only a single BCC lesion with no impact on health status, while a significant proportion is affected repeatedly with new primary tumors at various body sites. Approximately 29% of patients with a first BCC will develop at least 1 more lesion during their lifetime. The candidate predictors for multiple BCC development include younger age and a superficial BCC subtype at the time of the first diagnosis, red hair phenotype, initial or frequent tumor location on the trunk or on the upper limbs, and male gender. The pathogenesis of multiple BCC development does not seem to be related to greater UVR exposure. Individual genetic susceptibility may have a greater impact than extrinsic factors. In clinical practice, it is meaningful to estimate the probability of new BCC development in patients who have an initial lesion. A reliable prediction model for individualized risk stratification remains a subject of continued research; however, a focus on the risk factor profile is beneficial for clinical screening and may help clinicians to determine the individuals who should be followed up more closely.